These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15149825)

  • 1. A comparative study of adduct formation between the anticancer ruthenium(III) compound HInd trans-[RuCl4(Ind)2] and serum proteins.
    Piccioli F; Sabatini S; Messori L; Orioli P; Hartinger ChG; Keppler BK
    J Inorg Biochem; 2004 Jun; 98(6):1135-42. PubMed ID: 15149825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a ruthenium(III)/NAMI-A adduct with bovine serum albumin that exhibits a high anti-metastatic activity.
    Liu M; Lim ZJ; Gwee YY; Levina A; Lay PA
    Angew Chem Int Ed Engl; 2010 Feb; 49(9):1661-4. PubMed ID: 20127775
    [No Abstract]   [Full Text] [Related]  

  • 3. Platinum group metallodrug-protein binding studies by capillary electrophoresis - inductively coupled plasma-mass spectrometry: a further insight into the reactivity of a novel antitumor ruthenium(III) complex toward human serum proteins.
    Polec-Pawlak K; Abramski JK; Semenova O; Hartinger CG; Timerbaev AR; Keppler BK; Jarosz M
    Electrophoresis; 2006 Mar; 27(5-6):1128-35. PubMed ID: 16440400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and reactivity of the aquation product of the antitumor complex trans-[Ru(III)Cl4(indazole)2]-.
    Cebrián-Losantos B; Reisner E; Kowol CR; Roller A; Shova S; Arion VB; Keppler BK
    Inorg Chem; 2008 Jul; 47(14):6513-23. PubMed ID: 18553904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity relationships for NAMI-A-type complexes (HL)[trans-RuCl4L(S-dmso)ruthenate(III)] (L = imidazole, indazole, 1,2,4-triazole, 4-amino-1,2,4-triazole, and 1-methyl-1,2,4-triazole): aquation, redox properties, protein binding, and antiproliferative activity.
    Groessl M; Reisner E; Hartinger CG; Eichinger R; Semenova O; Timerbaev AR; Jakupec MA; Arion VB; Keppler BK
    J Med Chem; 2007 May; 50(9):2185-93. PubMed ID: 17402720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A spectroscopic study of the reaction of NAMI, a novel ruthenium(III)anti-neoplastic complex, with bovine serum albumin.
    Messori L; Orioli P; Vullo D; Alessio E; Iengo E
    Eur J Biochem; 2000 Feb; 267(4):1206-13. PubMed ID: 10672032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploiting soft and hard X-ray absorption spectroscopy to characterize metallodrug/protein interactions: the binding of [trans-RuCl4(Im)(dimethylsulfoxide)][ImH] (Im = imidazole) to bovine serum albumin.
    Ascone I; Messori L; Casini A; Gabbiani C; Balerna A; Dell'Unto F; Castellano AC
    Inorg Chem; 2008 Oct; 47(19):8629-34. PubMed ID: 18722420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Probing the stability of serum protein-ruthenium(III) drug adducts in the presence of extracellular reductants using CE.
    Timerbaev AR; Foteeva LS; Rudnev AV; Abramski JK; Połeć-Pawlak K; Hartinger CG; Jarosz M; Keppler BK
    Electrophoresis; 2007 Jul; 28(13):2235-40. PubMed ID: 17557359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of apo-transferrin with anticancer ruthenium complexes NAMI-A and its reduced form.
    Mazuryk O; Kurpiewska K; Lewiński K; Stochel G; Brindell M
    J Inorg Biochem; 2012 Nov; 116():11-8. PubMed ID: 23010324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of ligand-exchange processes and the oxidation state of the antimetastatic Ru(III) complex NAMI-A by interactions with human serum albumin.
    Webb MI; Walsby CJ
    Dalton Trans; 2011 Feb; 40(6):1322-31. PubMed ID: 21210063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of anticancer ruthenium compounds with proteins: high-resolution X-ray structures and raman microscopy studies of the adduct between hen egg white lysozyme and AziRu.
    Vergara A; D'Errico G; Montesarchio D; Mangiapia G; Paduano L; Merlino A
    Inorg Chem; 2013 Apr; 52(8):4157-9. PubMed ID: 23517183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EPR as a probe of the intracellular speciation of ruthenium(III) anticancer compounds.
    Webb MI; Walsby CJ
    Metallomics; 2013 Dec; 5(12):1624-33. PubMed ID: 24057014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, structural characterization, solution chemistry, and preliminary biological studies of the ruthenium(III) complexes [TzH][trans-RuCl4(Tz)2] and [TzH][trans-RuCl4(DMSO)(Tz)].(DMSO), the thiazole analogues of antitumor ICR and NAMI-A.
    Mura P; Camalli M; Messori L; Piccioli F; Zanello P; Corsini M
    Inorg Chem; 2004 Jun; 43(13):3863-70. PubMed ID: 15206867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin.
    Bergamo A; Messori L; Piccioli F; Cocchietto M; Sava G
    Invest New Drugs; 2003 Nov; 21(4):401-11. PubMed ID: 14586207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of capillary electrophoresis-inductively coupled plasma mass spectrometry to comparative studying of the reactivity of antitumor ruthenium(III) complexes differing in the nature of counter-ion toward human serum proteins.
    Połeć-Pawlak K; Abramski JK; Ferenc J; Foteeva LS; Timerbaev AR; Keppler BK; Jarosz M
    J Chromatogr A; 2008 May; 1192(2):323-6. PubMed ID: 18433763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations.
    Vargiu AV; Robertazzi A; Magistrato A; Ruggerone P; Carloni P
    J Phys Chem B; 2008 Apr; 112(14):4401-9. PubMed ID: 18348562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biotransformations of anticancer ruthenium(III) complexes: an X-ray absorption spectroscopic study.
    Levina A; Aitken JB; Gwee YY; Lim ZJ; Liu M; Singharay AM; Wong PF; Lay PA
    Chemistry; 2013 Mar; 19(11):3609-19. PubMed ID: 23361836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruthenium metalation of proteins: the X-ray structure of the complex formed between NAMI-A and hen egg white lysozyme.
    Messori L; Merlino A
    Dalton Trans; 2014 Apr; 43(16):6128-31. PubMed ID: 24553967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The binding properties of two antitumor ruthenium(III) complexes to apotransferrin.
    Kratz F; Hartmann M; Keppler B; Messori L
    J Biol Chem; 1994 Jan; 269(4):2581-8. PubMed ID: 8300587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.